poisar

Stocks · News reference

Adicet Bio Reports Third Quarter 2026 Financial Results and Business Updates

Fiscal.ai

Adicet Bio announced its financial results for the third quarter of 2026, reporting a reduced net loss and providing updates on its clinical development programs.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Adicet Bio, Inc. (ACET)

    Filed: 2026-11-05 AccNo: 0001720580-26-000065 Size: 378 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits